MedPath

APELLIS PHARMACEUTICALS, INC

APELLIS PHARMACEUTICALS, INC logo
🇺🇸United States
Ownership
Public
Established
2008-01-01
Employees
706
Market Cap
$4.8B
Website
http://www.apellis.com

Clinical Trials

68

Active:37
Completed:17

Trial Phases

4 Phases

Phase 1:37
Phase 2:10
Phase 3:11
+1 more phases

Drug Approvals

2

FDA:2

Drug Approvals

Syfovre

Approval Date
Sep 16, 2025
FDA

Empaveli

Approval Date
Jul 30, 2025
FDA

Clinical Trials

Distribution across different clinical trial phases (61 trials with phase data)• Click on a phase to view related trials

Phase 1
37 (60.7%)
Phase 3
11 (18.0%)
Phase 2
10 (16.4%)
Not Applicable
3 (4.9%)

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

Not Applicable
Recruiting
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
Drug: APL-3007, pegcetacoplan (APL-2)
Other: Placebo, Syfovre
First Posted Date
2025-10-10
Last Posted Date
2025-10-10
Lead Sponsor
Apellis Pharmaceuticals, Inc.
Target Recruit Count
240
Registration Number
NCT07215390
Locations
🇺🇸

Bay Area Retina Associates - Walnut Creek, Walnut Creek, California, United States

🇺🇸

Cumberland Valley Retina Consultants (CVRC), Hagerstown, Maryland, United States

Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe

Not Applicable
Not yet recruiting
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
Drug: APL-2, Pegcetacoplan
First Posted Date
2025-10-09
Last Posted Date
2025-10-09
Lead Sponsor
Apellis Pharmaceuticals, Inc.
Target Recruit Count
36
Registration Number
NCT07214740

A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis

Not Applicable
Not yet recruiting
Conditions
FSGS
Interventions
Other: Placebo
First Posted Date
2025-10-09
Last Posted Date
2025-10-09
Lead Sponsor
Apellis Pharmaceuticals, Inc.
Target Recruit Count
270
Registration Number
NCT07213960
Locations
🇺🇸

Investigator Site 1, Chicago, Illinois, United States

🇺🇸

Investigator Site 2, New York, New York, United States

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

Phase 3
Not yet recruiting
Conditions
Delayed Graft Function
Deceased Donor Kidney Transplant
End Stage Renal Disease
Interventions
Other: Placebo
First Posted Date
2025-06-13
Last Posted Date
2025-06-13
Lead Sponsor
Apellis Pharmaceuticals, Inc.
Target Recruit Count
320
Registration Number
NCT07020832

Geographic Atrophy Long-Terms Outcomes Study

Completed
Conditions
Geographic Atrophy
First Posted Date
2024-07-12
Last Posted Date
2024-07-12
Lead Sponsor
Apellis Pharmaceuticals, Inc.
Target Recruit Count
255
Registration Number
NCT06499571
Locations
🇦🇺

Sydney West Retina, Westmead, New South Wales, Australia

🇫🇷

Centre Hospitalier de la Croix Rousse, Lyon Cedex 04, Rhone, France

🇩🇪

Universitaetsklinikum Muenster, Münster, Nordrhein Westfalen, Germany

and more 2 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.